Seizure News and Research

Latest Seizure News and Research

People suffering from vision loss are twice as likely to suffer from depression

People suffering from vision loss are twice as likely to suffer from depression as the general population. And many psychiatric medications can cause vision problems over time.

6 May 2014

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.

2 May 2014

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

A review by the American Academy of Neurology of available scientific research on the use of medical marijuana in brain diseases finds certain forms of medical marijuana can help treat some symptoms of multiple sclerosis (MS), but do not appear to be helpful in treating drug-induced (levodopa) movements in Parkinson's disease.

29 Apr 2014

Highlights from April 2014 issue of Mayo Clinic Health Letter

Here are highlights from the April issue of Mayo Clinic Health Letter.

26 Apr 2014

New FDA-approved device reduces seizures in patients with medication-resistant epilepsy

A recently FDA-approved device has been shown to reduce seizures in patients with medication-resistant epilepsy by as much as 50 percent. When coupled with an innovative electrode placement planning system developed by physicians at Rush, the device facilitated the complete elimination of seizures in nearly half of the implanted Rush patients enrolled in the decade-long clinical trials.

23 Apr 2014

Researchers discover that anti-seizure drug reduces alcohol consumption

Boston-Researchers from Boston University School of Medicine (BUSM) have discovered that the anti-seizure drug ezogabine, reduced alcohol consumption in an experimental model. The findings, reported in the American Journal of Drug and Alcohol Abuse, may lead to more effective treatments for alcoholism.

18 Apr 2014

Young people with epilepsy are more than twice as likely to be poisoned by medication

Children and young adults with epilepsy are more likely to suffer broken bones, burns and poisonings compared to those without the neurological disorder, new research has found.

15 Apr 2014

Experts create new definition for epilepsy

An expert task force has created a new definition for epilepsy that refines the scope of patients diagnosed with this brain disease. The study published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy, provides a greater level of detail to diagnose epilepsy by including individuals with two unprovoked seizures, and those with one unprovoked seizure and other factors that increase risk of seizure recurrence.

15 Apr 2014

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

4 Apr 2014

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy.

31 Mar 2014

Study links effect of gastric bypass surgery on glucose metabolism and islet function in hypoglycemia patients

University of Cincinnati (UC) researchers have discovered that altered islet cell function and reduced insulin clearance contribute to excessive post-meal insulin response in patients experiencing low blood sugar symptoms (hypoglycemia) following gastric bypass surgery.

29 Mar 2014

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.

27 Mar 2014

Study: Mood stabilizing drug may help prevent head and neck cancer

A new study indicates that a commonly used mood stabilizing drug may help prevent head and neck cancer. The study is published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

24 Mar 2014

Sea lions exposed to toxin in algae develop form of epilepsy that is similar to humans

California sea lions exposed to a toxin in algae develop a form of epilepsy that is similar to one in humans, according to a new study led by Stanford University School of Medicine researchers.

19 Mar 2014

Researcher detects higher rate of seizures among children with autism who were fed soy formula

A University of Wisconsin-Madison researcher has detected a higher rate of seizures among children with autism who were fed infant formula containing soy protein rather than milk protein.

14 Mar 2014

SAGE Therapeutics announces completion of $38 million Series C financing

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the successful completion of a $38 million Series C financing. OrbiMed Advisors, LLC, EcoR1 Capital Management, Foresite Capital Management and two undisclosed blue chip public investment funds joined existing investors Third Rock Ventures and ARCH Venture Partners.

13 Mar 2014

Three innovative tools to detect, test and initiate personalized drug treatment for seizures

A team of researchers from the National Institutes of Health, Emory University and Cedars-Sinai - specialists in identifying and treating very rare diseases - used three innovative tools to detect a previously unknown gene mutation, test potential therapies in the lab, and initiate personalized drug treatment for a boy with a lifelong history of uncontrollable seizures that caused significant impact on his cognitive and social development.

12 Mar 2014

FDA accepts Lundbeck's carbamazepine NDA for review

Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug (AED) carbamazepine. An action letter is anticipated before the end of 2014. Carbella is the proposed U.S. trade name for intravenous carbamazepine.

10 Mar 2014

FDA approves KALYDECO for people with cystic fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for KALYDECOTM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO was first approved in January 2012 for people with CF ages 6 and older who have at least one copy of the G551D mutation.

26 Feb 2014

Longer looks: Doctor training for ADHD, Obamacare and epilepsy, clues in a drop of blood

Jerry, 9 years old, dissolved into his Game Boy while his father described his attentional difficulties to the family pediatrician.

21 Feb 2014

Seizure News and Research

Latest Seizure News and Research

People suffering from vision loss are twice as likely to suffer from depression

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

AAN review finds certain forms of medical marijuana can help treat some symptoms of MS

Highlights from April 2014 issue of Mayo Clinic Health Letter

New FDA-approved device reduces seizures in patients with medication-resistant epilepsy

Researchers discover that anti-seizure drug reduces alcohol consumption

Young people with epilepsy are more than twice as likely to be poisoned by medication

Experts create new definition for epilepsy

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

Study links effect of gastric bypass surgery on glucose metabolism and islet function in hypoglycemia patients

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

Study: Mood stabilizing drug may help prevent head and neck cancer

Sea lions exposed to toxin in algae develop form of epilepsy that is similar to humans

Researcher detects higher rate of seizures among children with autism who were fed soy formula

SAGE Therapeutics announces completion of $38 million Series C financing

Three innovative tools to detect, test and initiate personalized drug treatment for seizures

FDA accepts Lundbeck's carbamazepine NDA for review

FDA approves KALYDECO for people with cystic fibrosis

Longer looks: Doctor training for ADHD, Obamacare and epilepsy, clues in a drop of blood

Everything you need to know about epilepsy eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Seizure News and Research

Latest Seizure News and Research

Everything you need to know about epilepsy eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in